Indegene Faces Tax Demand Linked to Transfer Pricing Adjustments

Indegene Limited has received a final income tax assessment order for Assessment Year 2023-24, imposing a tax demand of ₹43.69 crore stemming from transfer pricing adjustments totaling ₹123.41 crore. The company announced on May 5, 2026, that it is actively pursuing resolution for these adjustments through the Mutual Agreement Procedure (MAP) with the United States and domestic appellate processes, expressing confidence that it will mitigate any material adverse effect on its operations or financials.

Significance of the Tax and TP Issue

This tax assessment represents a potential financial liability for Indegene. The transfer pricing adjustments, which relate to how inter-company transactions are valued across borders, suggest a difference in opinion between the company and tax authorities. While Indegene remains optimistic about resolving the matter, the potential realization of this demand could impact profitability and cash flows. The ongoing appeals process will be crucial in determining the final financial outcome.

Indegene's Business Context

Indegene operates as a global digital transformation partner for the life sciences industry. Its business model involves extensive cross-border transactions, making transfer pricing a standard compliance consideration.

Potential Financial and Operational Impacts

Shareholders will monitor the progress of Indegene's appeals and MAP proceedings. The company's financial statements may reflect provisions or contingent liabilities related to this tax demand. Management's focus is on resolving this matter to minimize any financial or operational disruption.

The primary risk for Indegene is the potential obligation to pay the ₹43.69 crore tax demand if appeals are unsuccessful. Pursuing the MAP and domestic appeals will also incur costs, increasing operational expenses. Unfavorable rulings could impact the company's reputation and future tax strategies.

Industry Context

Indegene operates in the life sciences digital transformation space. Its peers, such as Coforge and LTIMindtree, also have substantial healthcare and life sciences verticals. However, specific tax assessment details for these competitors are not readily available for direct comparison on this issue.

Key Tracking Points for Investors

Investors will track updates on the progress and outcome of the Mutual Agreement Procedure (MAP) and the domestic appellate framework. Management commentary on the likelihood and timeline of resolution, along with any specific financial provisions disclosed in subsequent filings, will be key indicators.